Need A G, Nordin C, Horowitz M, Morris H A
Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, South Australia.
Metabolism. 1990 Apr;39(4 Suppl 1):53-4. doi: 10.1016/0026-0495(90)90274-g.
The effects of oral calcitriol (0.25 and 0.50 micrograms/d), together with calcium (1 g/d), on calcium absorption and bone resorption were measured in postmenopausal osteoporotic women with calcium malabsorption. Radiocalcium absorption was significantly improved and urinary hydroxyproline/creatinine excretion significantly reduced on both doses, but the higher dose caused an unacceptable incidence of hypercalcemia. In 49 patients treated for an average of 15 months with the lower dose, there was a nonsignificant gain in forearm bone mass of 0.4 +/- 0.3 mg/cm/mo (approximately 1/2% per annum) compared with a significant decrease in 17 untreated patients of 3.8 +/- 1.3 mg/cm/mo (approximately 5% per annum).
对伴有钙吸收不良的绝经后骨质疏松症女性，测定了口服骨化三醇（0.25和0.50微克/天）联合钙（1克/天）对钙吸收和骨吸收的影响。两个剂量的骨化三醇均使放射性钙吸收显著改善，尿羟脯氨酸/肌酐排泄显著减少，但较高剂量导致高钙血症的发生率不可接受。49例接受较低剂量治疗平均15个月的患者，前臂骨量非显著性增加0.4±0.3毫克/厘米/月（约每年1/2%），而17例未治疗患者前臂骨量显著减少3.8±1.3毫克/厘米/月（约每年5%）。
